Validation of Clinical and Molecular Characteristics of Favorable IMDC Risk in mRCC
Overview
This study validates the prognostic significance of a very favorable risk subgroup within the IMDC favorable risk category in metastatic renal cell carcinoma (mRCC). Patients in this subgroup demonstrated superior overall survival compared to standard favorable risk patients, supported by clinical and molecular analyses.
Background
The IMDC risk model stratifies mRCC patients into favorable, intermediate, and poor risk groups based on six clinical factors and remains relevant in the era of immune-oncology (IO) therapies. Despite advances in combination therapies, the benefit of IO regimens in favorable risk patients is unclear, possibly due to their angiogenic tumor profile. A very favorable risk subgroup within the favorable category, characterized by longer time from diagnosis to therapy, high performance status, and absence of certain metastases, has been proposed but requires further validation.
Data Highlights
Risk Group
Median Overall Survival (months)
95% Confidence Interval
Very Favorable (Tier 1)
64.8
58.8-70.8
Favorable (Entire Cohort)
45.6
42.0-50.4
Key Findings
The IMDC favorable risk group includes a very favorable risk subgroup (tier 1) defined by KPS ≥90%, diagnosis-to-therapy interval ≥3 years, and absence of brain, liver, or bone metastases.
Patients in the very favorable subgroup had a median overall survival of 64.8 months, significantly longer than the 45.6 months observed in the overall favorable risk group (HR 1.84, P < .001).
IO combination therapies have not demonstrated clear overall survival benefits in the favorable risk group, possibly due to an angiogenic rather than immunogenic tumor profile.
Transcriptomic and genomic analyses from the IMmotion151 trial support distinct molecular characteristics in the very favorable risk subgroup, correlating with clinical outcomes.
The study underscores the need for tailored treatment strategies for very favorable risk patients, who may not benefit from aggressive IO-based regimens.
Clinical Implications
Clinicians should recognize the heterogeneity within the IMDC favorable risk group, identifying patients with very favorable risk features who may have excellent prognosis with less intensive therapy. This stratification can guide personalized treatment decisions, potentially avoiding overtreatment with IO combinations in this subgroup. Further research is needed to optimize therapeutic approaches based on molecular profiles.
Conclusion
The validation of a very favorable risk subgroup within the IMDC favorable category highlights important prognostic and molecular distinctions in mRCC. These findings support more nuanced risk stratification to inform clinical management and therapeutic selection.
References
Schmidt et al 2021 -- Identification of a Very Favorable Risk Subgroup in mRCC
IMmotion151 Trial -- Atezolizumab plus Bevacizumab vs Sunitinib in Advanced RCC
by Martin Zarba, Eddy Saad, Karl Semaan, Talal El Zarif, Evan Ferrier, Connor Wells, Razane El Hajj Chehade, Naveen S. Basappa, Hedyeh Ebrahimi, Mahrukh Huseni, Romain Banchereau, Rana R. McKay, Lori Wood, Benoit Beuselinck, Cristina Suárez, Kosuke Takemura, Aly-Khan A. Lalani, Haoran Li, Lavinia Anne Spain, Arnoud J. Templeton, Thomas B. Powles, Georg A. Bjarnason, Guillermo de Velasco, Toni K. Choueiri, Daniel Y. C. Heng
